Details of the Drug

General Information of Drug (ID: DMACVEI)

Drug Name
Eflapegrastim
Synonyms SPI-2012
Indication
Disease Entry ICD 11 Status REF
Neutropenia 4B00.0 Approved [1]
Breast cancer 2C60-2C65 Phase 3 [2]
Affected Organisms
Humans
Cross-matching ID
UNII
UT99UG9QJX
DrugBank ID
DB15001
TTD ID
D04CKG
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Granulocyte colony-stimulating factor (CSF3) TT5TQ2W CSF3_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Breast tissue
The Studied Disease Breast cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Granulocyte colony-stimulating factor (CSF3) DTT CSF3 2.45E-03 -0.03 -0.09
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761148.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031953)
3 Company report (Sppirx)